Rani Therapeutics (RANI) Stock Forecast, Price Target & Predictions
RANI Stock Forecast
Rani Therapeutics stock forecast is as follows: an average price target of $10.00 (represents a 614.29% upside from RANI’s last price of $1.40) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
RANI Price Target
The average price target for Rani Therapeutics (RANI) is $10.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 614.29% upside from RANI's last price of $1.40.
RANI Analyst Ratings
According to 4 Wall Street analysts, Rani Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RANI stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Rani Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 24, 2024 | Annabel Samimy | Stifel Nicolaus | $10.00 | $4.11 | 143.31% | 614.29% |
| Mar 27, 2024 | Edward Nash | Canaccord Genuity | $9.00 | $3.18 | 183.02% | 542.86% |
| Jun 13, 2022 | Andreas Argyrides | Wedbush | $28.00 | $9.40 | 197.87% | 1900.00% |
The latest Rani Therapeutics stock forecast, released on Jun 24, 2024 by Annabel Samimy from Stifel Nicolaus, set a price target of $10.00, which represents a 143.31% increase from the stock price at the time of the forecast ($4.11), and a 614.29% increase from RANI last price ($1.40).
Rani Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $9.50 |
| Last Closing Price | $1.40 | $1.40 | $1.40 |
| Upside/Downside | -100.00% | -100.00% | 578.57% |
In the current month, the average price target of Rani Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rani Therapeutics's last price of $1.40. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 16, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 01, 2024 | Oppenheimer | Outperform | Initialise | |
| Jun 12, 2024 | Rodman & Renshaw | Buy | Initialise | |
| May 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 27, 2024 | Canaccord Genuity | Buy | Buy | Hold |
Rani Therapeutics's last stock rating was published by H.C. Wainwright on Oct 18, 2024. The company gave RANI a "Buy" rating, the same as its previous rate.
Rani Therapeutics Financial Forecast
Rani Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.96M |
| Avg Forecast | - | - | - | - | - | - | - | $108.33K | $130.00K | $130.00K | $325.00K | $162.50K | $630.00K | $490.00K |
| High Forecast | - | - | - | - | - | - | - | $108.33K | $130.00K | $130.00K | $325.00K | $162.50K | $630.00K | $490.00K |
| Low Forecast | - | - | - | - | - | - | - | $108.33K | $130.00K | $130.00K | $325.00K | $162.50K | $630.00K | $490.00K |
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00% |
Rani Therapeutics's average Quarter revenue forecast for Sep 21 based on 1 analysts is $630.00K, with a low forecast of $630.00K, and a high forecast of $630.00K. RANI's average Quarter revenue forecast represents a -67.87% decrease compared to the company's last Quarter revenue of $1.96M (Jun 21).
Rani Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-16.66M | $-15.82M | $-15.69M | $-13.65M | $5.88M | $-2.88M | $-5.19M |
| Avg Forecast | - | - | - | - | - | - | - | $-21.67K | $-26.00K | $-9.69M | $-65.00K | $-32.50K | $-34.23M | $-98.00K |
| High Forecast | - | - | - | - | - | - | - | $-21.67K | $-26.00K | $-7.75M | $-65.00K | $-32.50K | $-27.38M | $-98.00K |
| Low Forecast | - | - | - | - | - | - | - | $-21.67K | $-26.00K | $-11.63M | $-65.00K | $-32.50K | $-41.08M | $-98.00K |
| Surprise % | - | - | - | - | - | - | - | 769.18% | 608.56% | 1.62% | 210.06% | -181.05% | 0.08% | 52.93% |
1 analysts predict RANI's average Quarter EBITDA for Mar 22 to be $-65.00K, with a high of $-65.00K and a low of $-65.00K. This is -101.10% lower than Rani Therapeutics's previous annual EBITDA (Dec 21) of $5.88M.
Rani Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-17.34M | $-16.21M | $-15.97M | $-13.83M | $-13.22M | $-3.14M | $-5.49M |
| Avg Forecast | $-8.51M | $-8.07M | $-8.65M | $-9.66M | $-7.75M | $-8.36M | $-8.83M | $-11.56M | $-13.82M | $-10.06M | $-17.37M | $-13.03M | $-3.89M | $-4.63M |
| High Forecast | $-8.51M | $-8.07M | $-8.65M | $-9.66M | $-7.10M | $-8.36M | $-8.83M | $-11.56M | $-13.82M | $-8.04M | $-17.37M | $-13.03M | $-3.11M | $-4.63M |
| Low Forecast | $-8.51M | $-8.07M | $-8.65M | $-9.66M | $-9.04M | $-8.36M | $-8.83M | $-11.56M | $-13.82M | $-12.07M | $-17.37M | $-13.03M | $-4.67M | $-4.63M |
| Surprise % | - | - | - | - | - | - | - | 1.50% | 1.17% | 1.59% | 0.80% | 1.01% | 0.81% | 1.18% |
Rani Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RANI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Rani Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $7.10M | $7.24M | $6.32M | $6.19M | $5.95M | $15.82M | $3.46M |
| Avg Forecast | - | - | - | - | - | - | - | $574.68K | $689.62K | $689.62K | $1.72M | $862.03K | $3.34M | $2.60M |
| High Forecast | - | - | - | - | - | - | - | $574.68K | $689.62K | $689.62K | $1.72M | $862.03K | $3.34M | $2.60M |
| Low Forecast | - | - | - | - | - | - | - | $574.68K | $689.62K | $689.62K | $1.72M | $862.03K | $3.34M | $2.60M |
| Surprise % | - | - | - | - | - | - | - | 12.35% | 10.50% | 9.16% | 3.59% | 6.90% | 4.73% | 1.33% |
Rani Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RANI last annual SG&A of $7.10M (Dec 22).
Rani Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.70 | $-0.66 | $-0.66 | $-0.65 | $-0.68 | $-0.16 | $-0.29 |
| Avg Forecast | $-0.29 | $-0.28 | $-0.30 | $-0.34 | $-0.27 | $-0.29 | $-0.34 | $-0.40 | $-0.52 | $-0.52 | $-0.66 | $-0.49 | $-0.18 | $-0.18 |
| High Forecast | $-0.29 | $-0.28 | $-0.30 | $-0.34 | $-0.25 | $-0.29 | $-0.34 | $-0.40 | $-0.52 | $-0.52 | $-0.66 | $-0.49 | $-0.18 | $-0.18 |
| Low Forecast | $-0.29 | $-0.28 | $-0.30 | $-0.34 | $-0.31 | $-0.29 | $-0.34 | $-0.40 | $-0.52 | $-0.52 | $-0.66 | $-0.49 | $-0.18 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | 1.75% | 1.26% | 1.28% | 0.98% | 1.37% | 0.89% | 1.66% |
According to undefined Wall Street analysts, Rani Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RANI previous annual EPS of $NaN (undefined).
Rani Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VIRX | Viracta Therapeutics | $0.22 | $8.00 | 3536.36% | Buy |
| ALXO | ALX Oncology | $1.79 | $24.50 | 1268.72% | Buy |
| VINC | Vincerx Pharma | $0.19 | $2.00 | 952.63% | Buy |
| RANI | Rani Therapeutics | $1.46 | $10.00 | 584.93% | Buy |
| CABA | Cabaletta Bio | $2.75 | $16.33 | 493.82% | Buy |
| MOLN | Molecular Partners | $5.25 | $29.00 | 452.38% | Buy |
| BMEA | Biomea Fusion | $4.64 | $23.33 | 402.80% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| EYPT | EyePoint Pharmaceuticals | $8.02 | $22.00 | 174.31% | Buy |
| PHVS | Pharvaris | $18.49 | $42.00 | 127.15% | Buy |
| TYRA | Tyra Biosciences | $15.22 | $31.75 | 108.61% | Buy |
| CRVS | Corvus Pharmaceuticals | $7.39 | $12.50 | 69.15% | Buy |
| TRVI | Trevi Therapeutics | $4.50 | $6.00 | 33.33% | Buy |
| MNPR | Monopar Therapeutics | $30.68 | $29.50 | -3.85% | Buy |